Trial argues strongly for the development of 1st-line biomarker selected strategies in pancreatic ductal adenocarcinoma

ARV-766 well tolerated and shows promising clinical activity in metastatic castration-resistant prostate cancer

ASCO 2024: Highlights and analysis

ASCO 2024: Advances in NSCLC

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma

Osimertinib success in locally advanced EGFR-mutated NSCLC

Manageable safety profile with early efficacy of Tec-DR in NDMM

Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer

Lutetium-177–PSMA-617 improves self-reported pain and HRQoL in taxane-naïve patients with PSMA-positive mCRPC

Ivonescimab benefit for EGFR mutant NSCLC patients who failed TKI therapy

Monitoring ovarian function in oncology studies

Bortezomib and dexamethasone demonstrate efficacy benefit in key subgroups vs daratumumab, bortezomib, and dexamethasone in RRMM